$0.93
-0.02(-2.42%)
Mkt Cap $17M
$0.85
$2.03
52-Week Range
At A Glance
1
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections.
2
No significant events in the past 90 days.
$17M
Market Cap
—
Revenue
—
Net Income
Employees7
Fundamentals
How The Business Makes Money
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIK0001379006
ISINUS6300873022
CUSIP630087302
Phone203 937 6137
Address1 Controls Drive, Shelton, CT, 06484, US
SEC EDGAR